iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium

Rhea-AI Summary

On November 12, 2020, iBio (NYSE: IBIO) announced its participation in Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. The company will engage in one-on-one meetings with institutional investors and join a panel discussing the future of COVID-19 treatments. iBio is recognized for its plant-based biologics manufacturing and is advancing treatments like IBIO-100 for fibrotic diseases. The panel, led by Jim Molloy, will address upcoming diagnostics and therapies following major vaccine developments.

BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) --  iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners’ Virtual Healthcare Symposium on November 19, 2020.

In addition to participating in a series of one-on-one meetings with institutional investors throughout the day, iBio will participate on a panel hosted by Jim Molloy, Alliance Global Partners’ Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals, entitled “The Next Wave in COVID-19 Treatments: After PFE, AZN, MRNA & the Rest, What Should we Look for in the Next Set of COVID-19 Diagnostics and Treatments?”

Due to the format of the event, no webcast will be available.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming^® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s Glycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

What is the date of the upcoming healthcare symposium involving iBio?

iBio will participate in the Virtual Healthcare Symposium on November 19, 2020.

What type of meetings will iBio hold during the healthcare symposium?

iBio will hold one-on-one meetings with institutional investors throughout the day.

Who is hosting the panel discussion that iBio will participate in?

The panel discussion is hosted by Jim Molloy from Alliance Global Partners.

What topics will the panel discussion cover?

The panel will discuss the next wave in COVID-19 treatments and diagnostics.

What is IBIO-100 developed by iBio?

IBIO-100 is a treatment under development by iBio for fibrotic diseases.